Galapagos announces first milestone in osteoporosis collaboration with Lilly

Mechelen, Belgium; 18 July 2008 – Galapagos NV (Euronext: GLPG) announced today that it has reached the first milestone in its osteoporosis collaboration with Eli Lilly and Company (NYSE:LLY), triggering a payment of €1 million from Lilly.
In December 2007, Lilly and Galapagos initiated a program to develop new medicines for the treatment of osteoporosis.  The agreement provides Lilly access to 12 of Galapagos’ novel proprietary osteoporosis targets that play a role in bone formation.  Galapagos is responsible for the development of drug candidates through to Phase IIa clinical Proof of Concept.  Under the terms of the agreement, Lilly will have the exclusive option to further develop and commercialize these candidates on a worldwide basis.  Galapagos will have the right to further develop and commercialize compounds for which Lilly does not exercise its option.  In addition to the €3 million upfront payment received from Lilly, Galapagos is eligible to receive up to €88 million in discovery, development and regulatory milestones for each target program.  Furthermore, should a product be commercialized, Galapagos could receive up to €130 million of one-time sales milestones and up to double-digit royalties on worldwide sales of alliance products.
“The achievement of this first milestone within six months of initiating the alliance with Lilly demonstrates Galapagos’ ability to deliver on its commitments in line with expectations,” said Onno van de Stolpe, Galapagos’ CEO.  “Each milestone that Galapagos reaches in its pharma alliances reduces both the scientific and financial risk of these programs.”
About osteoporosis
Osteoporosis is principally an ageing -related disease, when hormone levels essential for maintaining bone density decline.  The development of osteoporosis is characterized by a clinically significant reduction in bone density.  The disease is four times as common in women as men.  The enormous health care costs associated with osteoporosis, estimated at $15 billion per year in the USA alone, are related to the greatly increased incidence of fractures in osteoporosis patients. 
About Galapagos
Galapagos (Euronext Brussels: GLPG; Euronext Amsterdam: GLPGA; OTC: GLPYY) is a drug discovery company with pre-clinical programs in bone and joint diseases and bone metastasis.  Its BioFocus DPI division offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.  BioFocus DPI also provides adenoviral reagents for rapid identification and validation of novel drug targets, compound libraries for drug screening as well as ADMET database products to select targets and compounds.  Galapagos currently employs 470 people and operates facilities in six countries, with global headquarters in Mechelen, Belgium.  More information about Galapagos can be found at
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.